Breathing new life into asthma diagnosis
Circassia Pharmaceuticals plc
Supporting Circassia as brand leader in asthma diagnosis and management through a thought leadership programme.
Asthma – an inflammatory disease – is often misdiagnosed or underdiagnosed. During inflammation, higher-than-normal levels of nitric oxide (NO) are released from the airways. The concentration of NO in exhaled breath, or fractional exhaled nitric oxide (FeNO), can help identify airway inflammation, and thereby support a diagnosis of asthma when other objective evidence is lacking.
Better diagnosis and management of asthma has the potential to deliver real savings to healthcare providers and systems.
Raising awareness of FeNO testing within healthcare professional, patient and government communities
Our remit as the global communication agency for Circassia – manufacturers of novel point-of-care FeNO measurement devices – is to help raise awareness of the value of FeNO testing within healthcare professional, patient and government communities. Whether using social platforms such as LinkedIn to educate and update respiratory professionals on new clinical guidelines; working with global and local patient advocacy groups on educational initiatives; or driving MP engagement, we continue to push Circassia forwards as market leaders in asthma diagnosis and management.
This was a
Project for Circassia